VARENICLINE (CHANTIX) CLINICAL UPDATE: Important Information for Quitlines and Quitline Counselors

This is a reminder that on Wednesday, September 13, 2017  from 2:00-3:30 PM ET the North American Quitline Consortium will host a webinar titled: VARENICLINE (CHANTIX) CLINICAL UPDATE: Important Information for Quitlines and Quitline Counselors.  Please note that the webinar will not be recorded and slides will not be made available after the event.

During this webinar Pfizer Scientist, Micheal Dutro, PharmD will discuss relevant new published clinical information on varenicline. Specific topics to be discussed during this webinar include: 

• Important recent updates to the US Chantix Label and the supporting studies:
  • EAGLES Study: Landmark trial evaluating  safety and efficacy of smoking cessation medications in smokers with and without psychiatric disease
  • Gradual Quit Study:  evaluating  a new method to quit with varenicline
  • Safety Updates
• Using lower doses of varenicline: effect on efficacy and tolerability
• Varenicline in a Quitline setting

At the conclusion of this webinar, participants will be able to:

1.     Explain the basic results of the EAGLES Study and the resulting updates to US Product Labels for Chantix and bupropion SR.

2.     Explore applicability of the gradual reduction method of quitting smoking with varenicline

3.     Explain new varenicline safety information and the effects of lower dosing on safety and efficacy.

4.     Evaluate the possible impact of varenicline in a Quitline setting.

We look forward to you joining us for the upcoming webinar if you have questions or concerns please email us at naqc@naquitline.org.

register now